AntibioticDB

Highest development stage: Preclinical

Development active

Gram-positive activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Specifically active against MSSA and MRSA (methicillin-sensitive and resistant Staphylococcus aureus). Progenitor of HY-133

Source: https://journals.asm.org/doi/10.1128/aac.00217-11

Citation (2): In Vitro Activity against Staphylococcus aureus of a Novel Antimicrobial Agent, PRF-119, a Recombinant Chimeric Bacteriophage Endolysin
By: Idelevich, Evgeny A.; von Eiff, Christof; Friedrich, Alexander W.; et al.

PRF-119

Bacteriophage lysin

Institute of Medical Microbiology - University Hospital Münster, Münster,Germany

2011